INTRODUCTION
============

Promoter regions of DNA replication-related genes contain a common regulatory sequence, 5′-TATCGATA, named the DNA replication-related element (DRE) ([@B1]). A specific DRE-binding factor (DREF) has been identified ([@B2]) and numerous studies have revealed that the DREF/DRE system is required for the expression of many genes involved in cell proliferation and the cell cycle ([@B3]). Computational analysis of *Drosophila* gene promoters revealed that DRE is one of the most prevalent motifs in core promoters ([@B4]). In fact immunostaining of polytene chromosomes with antiDREF antibody revealed that DREF binds to hundreds of interband regions on the polytene chromosomes ([@B5]). In addition SAGE analyses revealed that DRE exists in upstream regions of many genes expressed in proliferating cells in eye imaginal discs ([@B6]). RNAi-mediated knockdown of DREF in growing tissues also provided direct evidence that it is necessary for cell cycle and cell growth control ([@B7],[@B8]).

It is reported that DREF is a component of the TATA box-binding protein-related factor 2 (TRF2) complex ([@B9]), which interacts with basal transcription machinery ([@B10]). This complex is directed to promoters of the PCNA and DNA polymerase α 180 kDa genes and upregulates their expression ([@B9]). DNA-binding activity of DREF is inhibited by dMi-2, which is the ATPase of an ATP-dependent chromatin remodeling complex ([@B5]). In addition, a homeodomein protein Dll interacts with the DNA-binding domain of DREF and prevents its DRE-binding activity ([@B11]).

Overexpression of the DREF in eye imaginal discs induces ectopic S phase, apoptosis and inhibited photoreceptor cell differentiation, resulting in a rough eye phenotype in adults. Enhancement of this phenotype was observed in crosses of DREF-overexpressing flies with *Dll* mutants. This observation combined with molecular and biochemical analyses suggested that *Dll* is a negative regulator of DREF ([@B11],[@B12]).

By genetic screening of mutations that modify the rough eye phenotype, we searched for other genes that genetically interact with DREF. For example, the rough eye phenotype was suppressed by half dose reduction of the *trithorax* group genes *brahma* (*brm*), *osa* and *moira* (*mor*) ([@B12]) known to maintain expression patterns of homeotic genes ([@B13]). The three genes encode subunits of the BRM complex, a SWI/SNF class ATP-dependent chromatin remodeling complex in *Drosophila*, altering nucleosome structures to activate or repress gene transcription ([@B14],[@B15]). BRM complexes can be subclassified into BAP and PBAP types depending on their signature subunits ([@B16]). OSA is specific to BAP, and Polybromo and BAP170 are specific to PBAP complex. BRM, MOR and five other proteins (Snr1, BAP111, BAP60, BAP55 and Actin) are shared with both complexes ([@B16]). Recent studies have revealed functional differences between BAP and PBAP in cell cycle regulation ([@B17]), only BAP promoting G2/M progression. BRM complexes also genetically interact with cell cycle regulators, *E2F* and *cyclin E* ([@B18],[@B19]), suggesting a role in negatively controlling G1/S progression.

To clarify the relationship between DREF and BRM complexes, we searched for DRE or DRE-like sequences in 5′ flanking regions of *brm, osa* and *mor*, and found examples in the *osa* and *mor* genes. Binding of DREF to DRE in both genes could be demonstrated *in vitro* and *in vivo* and *luciferase* transient expression assays confirmed that DRE and DREF are important in their promoter activities. Furthermore, mRNA levels of *osa* and *mor* were reduced in DREF knockdown cells. These results indicate that transcription of *osa* and *mor* is regulated by the DRE/DREF regulatory pathway. In addition, mRNA levels of other BRM complex subunits and of its target gene, *string*/*cdc25*, were decreased by knockdown of DREF. These results taken together revealed that DREF is involved in regulation of BRM complexes and consequently the cell cycle.

MATERIALS AND METHODS
=====================

Fly strains
-----------

Fly strains were maintained at 25°C on standard food. Canton S flies were used as the wild-type strain. The UAS-*dDREF* transgenic fly line was described earlier ([@B12]) as was the transgenic fly line (line number 16) carrying GMR-GAL4 on the X chromosome ([@B20],[@B21]). *osa^2^*/*TM6B, P{PZ}osa^00090^*/*TM3* and *mor^1^*/*TM6B* were obtained from the Drosophila Genetic Resource Center.

Scanning electron microscopy
----------------------------

Adult flies were anesthetized, mounted on stages and observed under a VE-7800 (Keyence Inc., Osaka, Japan) scanning electron microscope in the high vacuum mode.

Oligonucleotides
----------------

For RT-PCR these primer pairs were chemically synthesized.

osa-F, 5′-CCCTGTCCCTGTCTTCTCAC

osa-R, 5′-GATGGAACACCGGTAACCAC

mor-F, 5′-CGACAAGGACGATGAAGAGG

mor-R, 5′-CGCTGATGATGATGTGGAAC

Rp49-F, 5′-GCTTCTGGTTTCCGGCAAGCTTCAAG

Rp49-R, 5′-GACCTCCAGCTCGCGCACGTTGTGCACCAGGAAC

DREF-F, 5′-GGCAATCTCCGTTGAATGACG

DREF-R, 5′-TTCACCTCCGAGAAGCCCTT

β-tubulin-F, 5′-AGTTCACCGCTATGTTCA

β-tubulin-R, 5′-CGCAAAACATTGATCGAG

brm-F, 5′-TGTGCAACCATCCGTTTATG

brm-R, 5′-GTCATGCATTGGGTCATCTG

snr1-F, 5′-ACAAGAAGTACCCGGGAATG

snr1-R, 5′-GCACATACTGTGGCTGCTTC

BAP55-F, 5′-GGACATCATTCCTTGCGAGT

BAP55-R, 5′-GGAACGGTCACGTAGTTGGT

BAP60-F, 5′-GTAGCAAAGATGTCGCAACG

BAP60-R, 5′-CCGGGAACAGGTTGAGTAGT

polybromo-F, 5′-CCTGAAACGGATCTTTACGC

polybromo-R, 5′-ATGTTCCGAAGTTCCTGGTG

BAP170-F, 5′-GCATCATCCATCCATCATCC

BAP170-R, 5′-GACGTCGTTACCACAACAGC

string-F, 5′-GTGGAGGAAAACAACTGCAG

string-R, 5′-TCCATGCTCATCAGTTCCAG

The following oligonucleotides were used for electrophoretic mobility shift assays as probes and competitors.

osaDRE1,

5′-GCCAAATACTCGTACGTATCGATACTATCGTGCGTGCTACCCGC

osaDRE1 comp,

5′-GCGGGTAGCACGCACGATAGTATCGATACGTACGAGTATTTGGC

osaDRE2,

5′-CCCAGAGTAGCGAGAAATCGATATCGATGCCAACTCATTTTTGCGTC

osaDRE2 comp,

5′-GACGCAAAAATGAGTTGGCATCGATATCGATTTCTCGCTACTCTGGG

morDRE1,

5′-CGATAACGACTGTCACAACAACATCGATTTAAATACCATCTC

morDRE1 comp,

5′-GAGATGGTATTTAAATCGATGTTGTTGTGACAGTCGTTATCG

morDRE2,

5′-CAGTGGAGATAGCTGAAATATCGATAACGACTGTCACAACAACATCG

morDRE2 comp,

5′-CGATGTTGTTGTGACAGTCGTTATCGATATTTCAGCTATCTCCACTG

morDRE3,

5′-GCTCTCAAACTGTACAATCGATGCTGAGTTACTATAGCCGTACG

morDRE3 comp,

5′-CGTACGGCTATAGTAACTCAGCATCGATTGTACAGTTTGAGAGC

To carry out chromatin immunoprecipitation assays, the following oligonucleotides were used. The reverse primer to amplify morDRE1, 2 was mor3′HindIII as described below.

osaDRE1-F, 5′-CGAAACGAGCACCGATAATG

osaDRE1-R, 5′-ACGAAGAAGCGAGCCTGTAC

osaDRE2-F, 5′-GCACGCCGTTTAATTTGAGT

osaDRE2-R, 5′-CTGGCGAATTAGCGATATTTG

morDRE1,2-F, 5′-GCTTCCACCAACCAATAGGT

morDRE3-F, 5′-CTCATGCGCTCTGCATTTTC

morDRE3-R, 5′-CGAAAAGCAGTACCCAGTAC

brmDRE1-F, 5′-ACATGTCCCCCTACCAAACC

brmDRE1-R, 5′-CTGAGCTACTGTTTGTCCAG

brmDRE2-F, 5′-CGCAAACGTGTGGAATCTGC

brmDRE2-R, 5′-CCCGGATCACAAGTTCATCG

brmDRE3-F, 5′-GGATTGTTAACTACACCCAGC

brmDRE3-R, 5′-GAGGATACCCACAAGAATGAC

BAP55DRE-F, 5′-TAAGCGACCAAAGCGATAGG

BAP55DRE-R, 5′-CGCGAAAATACTTCCGTCTG

BAP60DRE-F, 5′-TGACCCACCAATTGTCTTCC

BAP60DRE-R, 5′-CAAACGCTCGATAGTTGCAG

BAP170DRE-F, 5′-CCAATGTAGATTGGATGCTG

BAP170DRE-R, 5′-ACAGCAGAGTTGCATTCACG

actin5C-F, 5′-CTCCATCATGAAGTGTGATGTG

actin5C-R, 5′-CGTACTCCTGCTTGGACGTC

Plasmid construction
--------------------

To construct the plasmids p5′-415osawt-luc and p5′-894morwt-luc, PCR was performed using *Drosophila* genomic DNA as a template and the following primers in combination: osa5′KpnI, 5′-GGTACCGCCACGAATAAGGCTTTCTAG and osa3′HindIII, 5′-AAGCTTCTGCACAGGCTGCACATACT; mor5′KpnI, 5′-GGTACCTCTCGCTCTCTTCCTCTTCG and mor3′HindIII, 5′-AAGCTTAGCCAATAAACGCTGCGTTG. PCR products were digested with KpnI and HindIII and inserted between the KpnI and HindIII sites of the PGVB plasmid (Toyo Ink., Tokyo, Japan).

Mutant constructs were created using a QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to manufacturer\'s protocol. Oligonucleotide pairs carrying base substitutions in the region of interest were used as primers.

osaDRE1mut,

5′-GCCAAATACTCGTACGTcgCGAgcCTATCGTGCGTGCTACCCGC

osaDRE1mut comp,

5′-GCGGGTAGCACGCACGATAGgcTCGcgACGTACGAGTATTTGGC

osaDRE2αmut,

5′-CCCAGAGTAGCGAGAAATCGATcgCGAgGCCAACTCATTTTTGCGTC

osaDRE2αmut comp,

5′-GACGCAAAAATGAGTTGGCcTCGcgATCGATTTCTCGCTACTCTGGG

osaDRE2βmut,

5′-CCCAGAGTAGCGAGAAcgCGAgcTCGATGCCAACTCATTTTTGCGTC

osaDRE2βmut comp,

5′-GACGCAAAAATGAGTTGGCATCGAgcTCGcgTTCTCGCTACTCTGGG

osaDRE2αβmut,

5′-CCCAGAGTAGCGAGAAcgCGAgcgCGAgGCCAACTCATTTTTGCGTC

osaDRE2αβmut comp,

5′-GACGCAAAAATGAGTTGGCcTCGcgcTCGcgTTCTCGCTACTCTGGG

morDRE1mut,

5′-CGATAACGACTGTCACAACAACcgCGAgTTAAATACCATCTC

morDRE1mut comp,

5′-GAGATGGTATTTAAcTCGcgGTTGTTGTGACAGTCGTTATCG

morDRE2mut,

5′-CAGTGGAGATAGCTGAAATcgCGAgcACGACTGTCACAACAACATCG

morDRE2mut comp,

5′-CGATGTTGTTGTGACAGTCGTgcTCGcgATTTCAGCTATCTCCACTG

morDRE3mut,

5′-GCTCTCAAACTGTACAcgCGAgGCTGAGTTACTATAGCCGTACG

morDRE3mut comp,

5′-CGTACGGCTATAGTAACTCAGCcTCGcgTGTACAGTTTGAGAGC

Cell culture
------------

Schneider (S2) cells were cultured in M3(BF) medium ([@B22]), supplemented with 10% fetal bovine serum (FBS) at 25°C in 5% CO~2~.

DNA transfection into cells and luciferase assays
-------------------------------------------------

Approximately 1 × 10^5^ S2 cells were plated 24 h before transfection, then 500 ng of reporter plasmid and 1 ng of pAct5C-seapansy as an internal control were cotransfected into the cells using CellFectin reagent (Invitrogen). At 48 h after transfection, cells were harvested and luciferase activities were measured using the Dual-Luciferase Reporter assay system (Promega, Madison, WI, USA). All assays were performed within the range of linear relation of activity to incubation time and values were normalized to *Renilla* luciferase activity. Transfections were performed several times with at least two independent plasmid preparations.

For double-stranded RNA (dsRNA) interference experiments, 30 μg of DREF dsRNA or LacZ dsRNA in FBS-free M3(BF) medium were added to 1 × 10^6^ S2 cells for 1 h. dsRNA-free incubation was conducted as a control for 1 h in FBS-free M3(BF). After the incubation, 4 v of M3(BF) medium containing 10% FBS were added. After 72 h of RNAi treatment, 1 × 10^5^ cells were cotransfected with reporter genes, 2 μg of reporter plasmid and 1 ng of pAct5C-seapansy plasmids, with the aid of Cell-Fectin reagents (Invitrogen, Carlsbad, CA, USA). At 48 h after transfection, luciferase activity was measured as described above.

Western immunoblot analysis
---------------------------

S2 cells (1 × 10^6^) were collected and lysed as described earlier ([@B23]). They were applied to 10% SDS--polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA) in transfer buffer (50 mM borate--NaOH, pH 9.0, 20% methanol). The blotted membranes were incubated with antiDREF monoclonal antibodies ([@B2]) at 1:10 000 dilution or antiTubulin IgG (Sigma, St Louis, MO, USA) at 1:5000 for 16 h at 4°C. The bound antibodies were detected with peroxidase-conjugated goat antimouse IgG and the ECL system (GE Healthcare, Little Chalfont, UK) according to the manufacturer\'s recommendations, and images were analyzed with a Lumivision Pro HSII image analyzer (Aisin Seiki, Aichi, Japan).

Electrophoretic mobility shift assays
-------------------------------------

Electrophoretic mobility shift assays were performed as reported previously ([@B1]), with minor modifications. Preparation of Kc cell nuclear extracts was described elsewhere ([@B1]). They were mixed with double-stranded ^32^P-labeled synthetic oligonucleotides (100 000 cpm) in a reaction buffer \[15 mM HEPES, pH 7.6, 60 mM KCl, 0.1 mM EDTA, 1 mM DTT, 12% glycerol and 0.1 mg/ml poly(dI-dC)\], and incubated for 15 min at 0°C. When necessary, unlabeled oligonucleotides were added as competitors at this step. DNA--protein complexes were electrophoretically resolved on 4% polyacrylamide gels in 50 mM Tris-borate, pH 8.3, 1 mM EDTA and 2.5% glycerol. The gels were dried and autoradiographed.

Electrophoretic mobility shift assays were also performed in the presence of antiDREF monoclonal antibody 1, antiDREF monoclonal antibody 4 ([@B2]) or normal mouse IgG as a control. Kc cell nuclear extracts were mixed with each antibody, incubated for 2 h at 0°C and added to mixtures containing ^32^P-labeled synthetic oligonucleotides (100 000 cpm). After 15 min incubation at 0°C, electrophoresis was carried out as described above.

Chromatin immunoprecipitation assays
------------------------------------

We performed chromatin immunoprecipitation using a Chip Assay kits as recommended by the manufacturer (Upstate, Lake Placid, NY, USA) ([@B24]). Approximately 1 × 10^7^ S2 cells were fixed in 1% formaldehyde at 37°C for 10 min and then quenched in 125 mM glycine for 5 min at 25°C. The cells were then washed in PBS containing protease inhibitors (1 mM PMSF, 1 μg/ml aprotinin and 1 μg/ml pepstatin A) and lysed in SDS lysis buffer. Lysates were sonicated to break DNA and the sonicated cell supernatants were diluted 10-fold in chip dilution buffer. Supernatant was precleared with Protein A Agarose/Salmon Sperm DNA (50% slurry) for 30 min at 4°C. After brief centrifugation, each supernatant was incubated with 1 μg of the rabbit IgG or antiDREF polyclonal antibody for 16 h at 4°C. Protein A Agarose/Salmon Sperm DNA (50% slurry) was added, with incubation for 1 h at 4°C. After washing, immunoprecipitated DNA was eluted with elution buffer (1% SDS, 0.1 M NaHCO~3~). Then the protein--DNA crosslinks were reversed by heating at 65°C for 4 h. After deproteinization with proteinase K, DNA was recovered by phenol--chloroform extraction and ethanol precipitation.

The immunoprecipitated DNA fragments were detected by quantitative real-time PCR using SYBR Premix Ex Taq (Takara, Kyoto, Japan) and the ABI PRISM® 7000 Sequence Detection System (Applied Biosystems, Tokyo, Japan). Primer pairs for PCR were described above.

Quantitative RT-PCR
-------------------

S2 cells were exposed to 30 μg of dsRNA and at 5 days after dsRNA treatment total RNA was isolated using Trizol® Reagent (Invitrogen). The cDNA was prepared with a Takara high fidelity RNA PCR kit using the oligo dT primer (Takara) for PCR with SYBR Premix Ex Taq (Takara) and the ABI PRISM® 7000 Sequence Detection System (Applied Biosystems). *Ct* values were normalized to that of the Rp49 gene.

RESULTS
=======

Half reduction of the *osa* or *mor* gene dose suppresses the DREF-induced rough eye phenotype
----------------------------------------------------------------------------------------------

Overexpression of DREF-induced ectopic DNA synthesis and apoptosis, and inhibited photoreceptor cell differentiation in eye imaginal discs so that adult flies exhibited a severe rough eye phenotype ([@B12]) ([Figure 1](#F1){ref-type="fig"}A and B), but their viability and fertility were normal. Therefore, we utilized these flies as a genetic tool for screening of mutations that can modify the rough eye phenotype ([@B11],[@B25; @B26; @B27]). Figure 1.*osa* and *mor* genes genetically interact with DREF. Scanning electron micrographs of adult eyes. DREF overexpressing flies (*GMR-GAL4/GMR-GAL4*; *UAS-DREF/UAS-DREF*) were crossed with *osa* or *mor* mutant flies and developed at 28°C. (**A, B**) *GMR-GAL4/+*; *UAS-DREF/+*; *+/+*. (**C, D**) *GMR-GAL4/+*; *UAS-DREF/+*; *osa^2^/+*. (**E, F**) *GMR-GAL4/+*; *UAS-DREF/+*; *P{PZ}osa^00090^/+*. (**G, H**) *GMR-GAL4/+*; *UAS-DREF/+*; *mor^1^/+*. (A, C, E, G) Scale bars are for 50 μm. (B, D, F, H) Scale bars are for 12.5 μm.

Previously we reported that half dose reduction of the *trithorax* group genes, *osa* and *mor* suppressed the DREF-induced rough eye phenotype ([@B12]). Here, we further confirmed that the F1 progeny of crosses between the DREF overexpressing strain and *osa^2^, osa^00090^* or *mor^1^* mutant flies showed suppression of the rough eye phenotype ([Figure 1](#F1){ref-type="fig"}C--H). Although their eyes were modestly rough, fused ommatidia were not apparent, suggesting that *osa* and *mor* are DREF target genes or positive regulators of the DRE/DREF regulatory pathway.

The 5′ flanking regions of the *osa* and *mor* genes contain DRE and DRE-like sequences
---------------------------------------------------------------------------------------

On the basis of our evidence that *osa* and *mor* might be DREF target genes, we searched for DRE or DRE-like sequences within 1.4 kb genomic regions from the transcription initiation sites of each of these genes. It has been described that DRE within such regions can upregulate transcription, a central 6 bp of DRE being sufficient for DREF to bind and activate the promoter ([@B1],[@B28]).

In the 5′ flanking region of the *osa* gene, one DRE and two DRE-like sequences were identified, and named DRE1 (−14 to −21), DRE2α (−243 to −250) and DRE2β (−249 to −256) ([Figure 2](#F2){ref-type="fig"}A). DRE1 was found to perfectly match the 8 bp DRE sequence, 5′-TATCGATA, while DRE2α and DRE2β each, matched 7 out of 8 bp. Figure 2.DRE and DRE-like sequences in the 5′ flanking regions of the *osa* and *mor* genes. Transcription initiation site is numbered as +1. (**A**) A schematic representation of DREs in the *osa* gene. (**B**) A schematic representation of DREs in the *mor* gene.

In the promoter region of the *mor* gene, one DRE and two DRE-like sequences were found. They were named DRE1 (−2 to −9), DRE2 (−26 to −33) and DRE3 (−718 to −725) ([Figure 2](#F2){ref-type="fig"}B), DRE2 perfectly matching the consensus DRE sequence and DRE1 and DRE3 showing identity in 6 out of 8 bp. Since all of these sites were detected in located at positions within 1.4 kb of the transcription initiation site, they are good candidate transcriptional regulatory sites for the *osa* and *mor* genes.

Roles of DRE sites in *osa* and *mor* gene promoter activities
--------------------------------------------------------------

To examine the roles of the DREs in *osa* promoter activity, we carried out luciferase transient expression assays in cultured *Drosophila* S2 cells. We constructed a *osa* promoter--luciferase fusion plasmid and derivatives carrying mutations in one or more of DRE1, DRE2α and DRE2β. These plasmids were transfected into S2 cells and luciferase activities were measured. Mutation in DRE1 (osa-DRE1mut) reduced the promoter activity by 49% relative to that of the wild-type promoter. Mutations in DRE2α (osa-DRE2αmut) and DRE2β (osa-DRE2βmut) reduced the promoter activity by 21 and 19%, respectively. Mutations in both DRE2α and DRE2β (osa-DRE2αβmut) reduced it by 20%. Mutations in all DREs (osa-DRE1 and 2αβmut) reduced the promoter activity by 76% ([Figure 3](#F3){ref-type="fig"}A). These results indicate that DRE1 mainly acts for activation of the *osa* promoter while DRE2 might have a supporting role. Figure 3.Effects of mutations in DRE sites in the 5′ flanking region of the *osa* and *mor* genes on their promoter activities. *osa* or *mor* promoter--luciferase fusion plasmids were transfected into S2 cells. Luciferase activities are expressed relative to wild-type *osa* (**A**) and *mor* (**B**) promoters. Mean values with standard deviations from three independent transfections are shown. The white box, wild-type DRE; the black box, mutant DRE.

The roles of DREs in *mor* promoter activity were examined in a similar way. Mutations in any one of three DREs alone exerted no effects on *mor* promoter activity and only slight reduction was noted with mutations in any two of the three. However, when all three DREs were mutated simultaneously, promoter activity was decreased by 73% ([Figure 3](#F3){ref-type="fig"}B). These results revealed that all DREs can contribute to *mor* promoter activation and any one appears to be sufficient for activity.

Effects of knockdown of the *DREF* gene on *osa* and *mor* gene promoter activity
---------------------------------------------------------------------------------

Endogenous *osa* and *mor* gene expression in RNAi-mediated DREF knockdown cells was examined to demonstrate that *osa* and *mor* are DREF target genes. Total RNAs from dsRNA-treated S2 cells were isolated and quantitative RT-PCR was carried out to measure the level of mRNAs. The DREF mRNA level was reduced by 95% in DREFdsRNA-treated cells, but was not changed in LacZdsRNA-treated cells ([Figure 4](#F4){ref-type="fig"}A). Under these conditions, the level of *osa* mRNA was decreased to 32% and that of *mor* mRNA to 14% relative to those with no RNAi treatment ([Figure 4](#F4){ref-type="fig"}A). The *β-tubulin* gene was used as a negative control and its expression was not affected by DREFdsRNA treatment ([Figure 4](#F4){ref-type="fig"}A). Figure 4.DREFdsRNA treatment affects mRNA levels and promoter activities of *osa* and *mor*. (**A**) cDNAs were prepared from total RNA isolated from dsRNA-treated S2 cells and levels of *DREF, osa* and *mor* mRNAs were measured by quantitative RT-PCR. Fold differences against the amplification with no treatment are shown with standard deviations from three independent dsRNA treatments. *β-tubulin* was used as a negative control. (**B**) Cell extracts were analyzed by western blotting with antiDREF antibodies. (**C**) Promoter activities of *osa* and *mor* in dsRNA-treated cells. Luciferase activities relative to that of wild-type promoter in non-dsRNA-treated cells are shown with standard deviations from five independent transfections.

To further investigate the requirement of DREF for *osa* and *mor* promoter activity, we performed luciferase transient expression in DREF knockdown cells. DREFdsRNA or LacZdsRNA were added to S2 cells, and reduction of DREF protein was confirmed by western blotting. DREF protein was not detectable at 2, 4 and 6 days after DREFdsRNA treatment, while no change was evident in mock and LacZdsRNA-treated cells ([Figure 4](#F4){ref-type="fig"}B). The luciferase reporter plasmids were transfected into S2 cells at 3 days after RNAi treatment, and luciferase activities were determined. In DREFdsRNA-treated cells, the wild-type *osa* promoter activity was decreased to 61% and *mor* promoter activity to 51% of those in non-dsRNA treatment cells. The promoter activities of both genes were not changed in LacZdsRNA-treated cells ([Figure 4](#F4){ref-type="fig"}C).

To further confirm dependence of promoter activation by DREF on DREs, we measured promoter activities of all DRE-mutant promoters of both *osa* and *mor* genes. Although we expected that the promoter activities of DRE mutants would not change in DREF knockdown cells, *osa* and *mor* promoter activities were slightly but significantly decreased in DREFdsRNA-treated cells ([Figure 4](#F4){ref-type="fig"}C). These results suggest that DREF not only directly but also indirectly regulates the *osa* and *mor* gene transcription. It may be possible that some DREF target gene products activate the *osa* and *mor* gene transcription.

DREF binds to the DRE sequence *in vitro*
-----------------------------------------

Binding of DREF to DRE is essential for transcriptional activation. We therefore investigated whether DREF has binding ability to the DRE sequences in the *osa* and *mor* promoter regions by electrophoretic mobility shift assays. ^32^P labeled DRE-containing oligonucleotides were mixed with *Drosophila* Kc cell nuclear extracts and DNA--protein complexes were detected with oligonucleotides containing osaDRE1 ([Figure 5](#F5){ref-type="fig"}A) or osaDRE2 ([Figure 5](#F5){ref-type="fig"}B). On addition of non-labeled DRE oliognucleotides as competitors, shifted bands were diminished ([Figure 5](#F5){ref-type="fig"}A and B). Addition of a competitor carrying mutations in each DRE did not affect the complex formation with osaDRE1 and osaDRE2 ([Figure 5](#F5){ref-type="fig"}A and B). The shifted band with osaDRE1 was decreased by the addition of a 100-fold excess of DRE1mut competitor, while those with osaDRE2 were not, suggesting the DRE1mut competitor oligonucleotide to possess an additional DREF-binding site. To confirm that the DRE--protein complex contains DREF, we added antiDREF monoclonal antibodies to the binding reaction. The addition of antiDREF 1, which binds to the DNA-binding domain of DREF ([@B2]), inhibited the complex formation with osaDRE1 and osaDRE2 ([Figure 5](#F5){ref-type="fig"}A and B). Furthermore, the band with osaDRE1 or osaDRE2 was supershifted by addition of antiDREF 4 ([@B2]) ([Figure 5](#F5){ref-type="fig"}A and B). These results indicate that DREF indeed form complexes with osaDRE1 and osaDRE2. Figure 5.Complex formation between *osa* DREs and Kc cell nuclear extracts. ^32^P-labeled double-stranded oligonucleotides osaDRE1 (**A**) and osaDRE2 (**B**) were incubated with Kc cell nuclear extracts in the presence of the indicated competitor oligonucleotides or antiDREF monoclonal antibodies. The amounts of competitors were 25-, 50- or 100-fold molar ratios for the osaDRE1 probe (A) and 100- or 400-fold molar ratios for the osaDRE2 probe (B). Mock, normal mouse IgG; Mab1, antiDREF monoclonal antibody 1; Mab4, antiDREF monoclonal antibody 4.

We also examined whether DREF can bind to DREs of the *mor* gene in the similar way. DNA--protein complexes were detected with the oligonucleotides morDRE1, morDRE2 and morDRE3 as probes ([Figure 6](#F6){ref-type="fig"}A--C). Since more nuclear extract was required to detect the DNA--protein complex with morDRE1, DREF appears to have lower affinity for morDRE1 than for the others. Each of the shifted bands disappeared on adding non-labeled DRE oliognucleotides as competitors, while competitor oligonucleotides carrying mutations in the DRE sequences exerted no effect ([Figure 6](#F6){ref-type="fig"}A--C). To further verify the existence of DREF in the complex with morDRE oligonucleotides, antiDREF monoclonal antibodies were added to the binding reaction. The addition of the antiDREF 1 inhibited the complex formation with morDRE2 and morDRE3 ([Figure 6](#F6){ref-type="fig"}B and C). The shifted bands with morDRE2 and morDRE3 were supershifted by adding antiDREF 4 ([Figure 6](#F6){ref-type="fig"}B and C). These results indicate that DREF form complexes with the oligonucleotides morDRE2 and morDRE3. Figure 6.Complex formation between *mor* DREs and Kc cell nuclear extracts. ^32^P-labeled double-stranded oligonucleotides morDRE1 (**A**), morDRE2 (**B**) and morDRE3 (**C**) were incubated with Kc cell nuclear extracts in the presence of the indicated competitor oligonucleotides or antiDREF monoclonal antibodies. The amounts of competitors were 25-, 50- or 100-fold molar ratios for the morDRE1 probe (A) and 100- or 400-fold molar ratios for the morDRE2 (B) and morDRE3 probes (C). Mock, normal mouse IgG; Mab1, antiDREF monoclonal antibody 1; Mab4, antiDREF monoclonal antibody 4.

Although addition of antiDREF 1 to the binding reaction only marginally affected the complex formation with morDRE1, the shifted band was at least partially supershifted by adding antiDREF 4 ([Figure 6](#F6){ref-type="fig"}A). These results suggest that not only DREF but also other protein(s) can form complexes with morDRE1.

DREF binds to the genomic regions containing DRE and DRE-like sequences of the *osa* and *mor in vivo*
------------------------------------------------------------------------------------------------------

Based on the observation that DREF has ability to bind to *osa* and *mor* DRE sequences *in vitro*, we further examined DREF binding under cellular conditions by chromatin immunoprecipitation assays using affinity purified antiDREF polyclonal antibodies. osaDRE1 and osaDRE2 could be considerably amplified from the immunoprecipitates with antiDREF IgG. Amplification of osaDRE1 was 21-fold and that of osaDRE2 was 14-fold compared with amplification from the immunoprecipitates with control IgG, while amplification of Act5C genomic region was only 1.5-fold ([Figure 7](#F7){ref-type="fig"}). Thus, we concluded that DREF binds to the osaDRE1- and osaDRE2-containing genomic region in cultured cells. Figure 7.Binding of DREF to the DRE-containing genomic regions of the *osa* and *mor* genes. Crosslinked chromatin of S2 cells was immunoprecipitated with either antiDREF IgG or control rabbit IgG. The genomic regions containing osaDRE1, osaDRE2, morDRE1, 2 or morDRE3 were amplified by real-time PCR and compared with the amplification from the immunoprecipitates with the control IgG.

Amplification of the region containing morDRE1 and 2 from the immunoprecipitates with antiDREF IgG was 3.3-fold in comparison with amplification of *Act5C* gene locus, but morDRE3 was amplified only 0.9-fold ([Figure 7](#F7){ref-type="fig"}). We therefore conclude that DREF does not bind to the genomic region containing morDRE3 *in vivo*. It should be noted that morDRE3 matches only six out of the eight bases canonical DRE and appeared to have only a weak affinity for DREF in the electrophoretic mobility shift assay *in vitro* ([Figure 6](#F6){ref-type="fig"}C).

Knockdown of DREF in S2 cells reduces expression of several genes encoding components of BRM complexes
------------------------------------------------------------------------------------------------------

In the 5′ flanking regions of the genes coding for *BAP55, BAP60* and *BAP170*, DRE or DRE-like sequences were found. Although no DRE was found in the 5′ flanking region of *brm*, its second intron contains three DRE-like sequences, suggesting that these sequences might act as enhancer elements. The *snr1, BAP111* and *polybromo* genes carry no DRE or DRE-like sequences in their 5′ flanking regions or introns ([Table 1](#T1){ref-type="table"}). These findings suggest that DREF plays a role in activating the transcription of several genes encoding subunits of both BAP and PBAP complexes. Table 1.DRE or DRE-like sequences in and around the genes coding for subunits of BRM complexesGeneDRE or DRE-likePositionBAP*brm*5′-cATCGATA+881 to +874PBAP5′-cATCGATg+2208 to +22015′-cATCGATg+7120 to +7113*mor*5′-cATCGATt−9 to −25′-TATCGATA−33 to −265′-aATCGATg−725 to −718*BAP55*5′-aATCGATA−39 to −325′-aATCGATA−91 to −84*BAP60*5′-TATCGATA−209 to −2025′-gATCGATA−277 to −270*snr1*None--*BAP111*None--BAP*osa*5′-TATCGATA−21 to −145′-TATCGATg−250 to −2435′-aATCGATA−256 to −249PBAP*BAP170*5′-TATCGATA−16 to −95′-cATCGATA−29 to −225′-aATCGATt−442 to −435*Polybromo*None--

To examine whether DREF affects expression of these genes, mRNA levels of *brm, BAP55, BAP60, snr1, polybromo* and *BAP170* in DREF knockdown cells were measured by quantitative RT-PCR. The *brm* expression level in DREFdsRNA-treated cells was reduced to 25% relative to non-RNAi-treated cells. The mRNA levels for *BAP55* and *BAP60* were decreased to 24 and 29%, respectively ([Figure 8](#F8){ref-type="fig"}A). PBAP-specific *polybromo* and *BAP170* were also decreased to 12 and 20%, respectively ([Figure 8](#F8){ref-type="fig"}A). DREF is assumed to control PBAP expression as well as BAP. Expression of the *snr1* gene was not affected by knockdown of DREF ([Figure 8](#F8){ref-type="fig"}A). Figure 8.Effects of DREF knockdown on mRNA levels of other BRM complex components. (**A**) Total RNA was isolated from S2 cells treated with dsRNA and cDNA was prepared. mRNA levels were determined by quantitative RT-PCR. Fold differences versus no dsRNA treatment are shown as mean values with standard deviations from three independent dsRNA transfections. (**B**) DRE-containing regions were amplified from immunoprecipitates with antiDREF IgG. (**C**) mRNA level of stg in DREFdsRNA-treated cells.

To investigate whether DREF directly regulates *brm, BAP55, BAP60* and *BAP170*, we carried out chromatin immunoprecipitation assays. Genomic regions containing brmDRE1 (+881 to +874), brmDRE2 (+2208 to +2201) and brmDRE3 (+7120 to +7113) were not amplified from immunoprecipitates with antiDREF IgG ([Figure 8](#F8){ref-type="fig"}B). It is therefore not likely that these DREs in the second intron of the *brm* gene act as enhancer elements. DRE-containing regions of *BAP55, BAP60* and *BAP170* were amplified by 9-, 12- and 18-fold, respectively ([Figure 8](#F8){ref-type="fig"}B). Therefore, DREF appears to bind to DREs in these genes and directly activates *BAP55, BAP60* and *BAP170* transcription.

It is reported that the OSA-containing BAP complex is necessary for G2/M progression through *string (stg)*/*cdc25* promoter activation ([@B17]). We therefore examined mRNA levels of *stg* in DREF knockdown cells. Quantitative RT-PCR revealed 80% decrease ([Figure 8](#F8){ref-type="fig"}C).

DISCUSSION
==========

In this study, we demonstrated that both *osa* and *mor* are DREF target genes. Thus *osa* and *mor* promoters exhibited decreased activities when carrying mutations in their DREs and after knockdown of DREF in cultured cells. In addition, levels of *osa* and *mor* mRNAs were reduced in DREF knockdown cells. Third, DREF can bind to DREs of *osa* and *mor in vitro*, and binding of DREF to the genomic regions containing DREs of both genes was observed in cultured cells. These results showed that DRE and DREF are important for *osa* and *mor* promoter activation. Promoters having mutations in all DREs of both *osa* and *mor* genes, however, still retained some activity. It is therefore possible that another element(s) and/or unknown factor(s) regulated by DREF are involved in *osa* and *mor* transcriptional activation. The observed rescue of the DREF-induced rough eye phenotype by a reduction in the *osa* and *moira* gene dosage is consistent with the idea that the *osa* and *moira* gene transcription is activated by DREF. However, we cannot exclude the possibility that the rescue could also be affected by a mechanism involving protein--protein interactions between DREF and BAP/PBAP at the promoters of cell cycle-regulated genes. Further analyses are necessary to address this point.

Both *osa* and *mor* encode components of the BRM complex ([@B16],[@B29; @B30; @B31]), which is a SWI/SNF type ATP-dependent chromatin remodeling complex conserved from yeast to human ([@B14]), with two forms, BAP and PBAP. OSA is a signature subunit of BAP, while PBAP contains Polybromo and BAP170 in its place ([@B16]). Localization patterns of OSA and Polybromo on polytene chromosomes differ, though several sites overlap ([@B16]). Whole-genome expression analysis also demonstrated that BAP and PBAP differentially regulate gene expression ([@B17]). For example, OSA negatively regulates expression of the *Wingless-target* genes and the *achaete/scute* gene ([@B32],[@B33]). OSA, Polybromo and BAP170 are all required for function of BRM complex ([@B17]). It is thought that OSA functions in recruitment of BAP to its target genes. MOR, a subunit common to both BAP and PBAP, is presumed to be essential for complex integrity, since its absence results in degradation of both forms ([@B17]). SRG3, which is a homolog of MOR in mammals, also acts for complex stabilization by protecting against proteasomal degradation ([@B34]). Therefore, OSA and MOR are essential subunits for function and stabilization of BRM complexes and DREF may control integrity of the BRM complex through activating *osa* and *mor* gene expression.

BAP and PBAP share seven subunits, BRM, MOR, Snr1, BAP111, BAP60, BAP55 and Actin ([@B16]). BRM is a catalytic subunit harboring the ATPase domain ([@B35]) and it was previously reported that reduction of the *brm* gene dose suppressed the DREF-induced rough eye phenotype ([@B12]). We also found the mRNA level of *brm* to be decreased in DREF knockdown cells. However, DRE-like sequences in the second intron, do not appear to function as regulatory elements, since DREF does not bind to the genomic region containing these sites *in vivo*. DREF may therefore indirectly control *brm* gene expression.

The genes coding for *BAP55* and *BAP60*, common subunits for BAP and PBAP, also contain DRE or DRE-like sequences in their 5′ flanking regions and are affected by DREF knockdown. DREF binds to the genomic regions containing their DREs *in vivo* and it is, therefore, possible that *BAP55* and *BAP60* are directly regulated by DREF. Furthermore, the PBAP-specific subunit *BAP170* carries a DRE in its 5′ flanking region. Reduction of mRNA levels of *osa, polybromo* and *BAP170* in DREF knockdown cells also is evidence that DREF contributes to the transcriptional regulation of both BAP and PBAP complexes. Therefore, DREF may regulate expression of genes coding for most subunits for both BAP and PBAP complexes and influence expression of many genes through chromatin remodeling.

It is reported that OSA-containing BAP complexes are necessary for G2/M progression through *stg* promoter activation while PBAP complexes are not ([@B17]). *stg* encodes a CDC25 phosphatase, which is required for G2/M progression ([@B36]). It is well known that DREF predominantly regulates the transcription of DNA replication-related genes ([@B1],[@B25],[@B37],[@B38]). Reduced *stg* mRNA has been reported in DREF-eliminated cells ([@B8]) and we also observed reduction of *stg* mRNA levels in DREF knockdown cells, as with *brm, osa* and *mor*. In addition to regulation of S phase entry, DREF thus appears to play an important role in G2/M transition by activating the BAP complex to promote cell cycling. We found two DRE-like sequences in the stg gene upstream region, −219 to −212 (5′-aATCGATg) and −591 to −584 (5′-TATCGATt). Therefore, DREF could regulate *stg* gene expression directly via binding to DRE-like and/or indirectly via activation of genes coding for BAP complexes. Further analysis is necessary to distinguish these possibilities.

BRM complexes are thought to inhibit S phase entry and mutations of *brm, osa* and *mor* suppress the rough eye phenotype induced by E2F/DP/p35 overexpression ([@B18]). The rough eye phenotype of a *cyclin E* hypomorphic mutant was also suppressed by BRM complex mutation through increase in the S phase ([@B19]). Therefore, BRM complexes appear to negatively regulate S phase entry, while DREF activates *E2F* gene transcription and promotes G1/S progression ([@B39]). Although *osa* is ubiquitously expressed in eye imaginal discs, it is most intensely expressed anterior to the morphogenic furrow where cells enter the G1 phase ([@B40]). Similarly, DREF is strongly expressed in this region ([@B12]). It is conceivable that DREF simultaneously activates both positive and negative regulators of G1/S progression. This kind of regulation may be necessary for fine tuning of cell cycle progression to inhibit excess S phase induction.
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